Neurocrine Biosciences (NBIX) Assets Average (2011 - 2026)

Neurocrine Biosciences has reported Assets Average for 16 years, with the latest figure at $4.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 28.78% year-over-year to $4.8 billion; the trailing twelve-month figure through Mar 2026 stood at $4.8 billion (up 28.78% YoY), and the FY2025 full-year result was $4.2 billion, up 19.8% from the prior year.
• Assets Average for Q1 2026 stood at $4.8 billion, up from $4.4 billion in the prior quarter.
• The five-year high for Assets Average was $4.8 billion in Q1 2026, with the low at $2.1 billion in Q3 2022.
• Historically, Assets Average has averaged $3.2 billion across 5 years, with a median of $3.4 billion in 2024.
• Annual changes were most pronounced in 2022 — Assets Average rose 4.41% — and 2024, when it soared 42.2%.
• Neurocrine Biosciences' Assets Average stood at $2.3 billion in 2022, then soared by 35.18% to $3.0 billion in 2023, then grew by 18.92% to $3.6 billion in 2024, then increased by 22.66% to $4.4 billion in 2025, then climbed by 7.2% to $4.8 billion in 2026.
• The last three Assets Average figures came in at $4.8 billion (Q1 2026), $4.4 billion (Q4 2025), and $4.1 billion (Q3 2025), per Business Quant data.